Non-small cell lung cancer · line 2 · Repotrectinib monotherapy (TRIDENT-1) — ROS1+ NSCLC (TKI-naive or post-prior ROS1-TKI)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-REPOTRECTINIB-NSCLC |
| ID | IND-PAN-NTRK-2L-REPOTRECTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 SRC-TRIDENT1-DRILON-2024 |
Notes
STUB — pending Clinical Co-Lead sign-off. Tumor-agnostic FDA approval 2024-06 for NTRK-fusion+ solid tumors post-prior TRK inhibitor. Listed under DIS-NSCLC for engine wiring (NSCLC NTRK fusion ~0.2% primary disease scope); separate per-disease Indications required for full tumor-agnostic application (CRC, sarcoma, salivary, etc.). TRIDENT-1 source already in KB (SRC-TRIDENT1-DRILON-2024).
Used By
No reverse references found in the YAML corpus.